Interestingly, two trials will evaluate the effect of SGLT2-i on renal outcome of patients with non-diabetic CKD: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With CKD (Dapa-CKD-Clinical-Trials.org identifier NCT03036150), and The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY, Clinical-Trials.org identifier NCT03594110). This evidence concerns the gene SLC5A2 and chronic kidney disease.